Description

Mitoxantron concentrate for infusions 2 mg/ml. 10 ml. vial №1

Ingredients:

Each 10 ml vial contains 20 mg of Mitoxantrone.

Dosage:

The dosage of Mitoxantron concentrate for infusions is individualized based on the patient’s condition, weight, and response to treatment. It is administered intravenously by a healthcare professional.

Indications:

Mitoxantron concentrate for infusions is indicated for the treatment of certain types of cancers, including acute myeloid leukemia and non-Hodgkin’s lymphoma.

Contraindications:

This medication is contraindicated in patients with known hypersensitivity to Mitoxantrone or any of the other ingredients in the formulation. It should not be used in pregnant women.

Directions:

Mitoxantron concentrate for infusions should only be administered by healthcare professionals experienced in the use of cytotoxic chemotherapy agents. The infusion should be given slowly to reduce the risk of side effects.

Scientific Evidence:

Mitoxantron is an anthracenedione antineoplastic agent that works by interfering with the growth and spread of cancer cells in the body. It has been extensively studied in clinical trials for its efficacy in treating various types of cancers.

Research has shown that Mitoxantron is effective in inducing remission in patients with acute myeloid leukemia and improving progression-free survival in those with non-Hodgkin’s lymphoma. Studies have also demonstrated its ability to penetrate the blood-brain barrier, making it useful in the treatment of certain brain tumors.

Additional Information:

• Mitoxantron concentrate for infusions may cause side effects such as nausea, hair loss, and myelosuppression. Regular monitoring of blood counts is essential during treatment.
• Patients should be advised to use effective contraception during and after treatment with Mitoxantron, as it can cause birth defects.